Test Price
2,800 AED✅ Home Collection Available
CAPN3 Gene Limb-Girdle Muscular Dystrophy Type 2A (LGMD2A) Next-Generation Sequencing DNA Test in UAE | 2,800 AED
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO-accredited NGS processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (available daily 8 AM–11 PM).
- Clinical Guidance: Telephonic post-test interpretation support from a Consultant Medical Geneticist.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The CAPN3 Genetic Test employs next‑generation sequencing (NGS) to analyze the entire coding region of the calpain‑3 gene. It detects pathogenic variants responsible for limb‑girdle muscular dystrophy autosomal recessive type 2A (LGMD2A), a progressive muscle‑wasting disorder. Definitive genetic diagnosis enables accurate prognosis, family planning, and access to emerging gene‑targeted therapies.
| Parameter | Our NGS Test | Closest Alternative |
|---|---|---|
| Method | Next‑Generation Sequencing (full CAPN3 gene) | Sanger Sequencing (limited exon coverage) |
| Diagnostic Precision | >99.9% analytical sensitivity | ~95% – may miss deep intronic variants |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
| Price (UAE) | 2,800 AED | 3,200–3,800 AED |
Physician Insight & Safety Protocols
“Understanding the implications of a genetic diagnosis for limb‑girdle muscular dystrophy can be challenging. This test provides definitive molecular confirmation, but it must be correlated with clinical findings, electromyography, and muscle histology. I strongly encourage pre‑ and post‑test genetic counselling to address family implications and to discuss emerging therapeutic options. A positive result does not define your future—supportive care and gene‑targeted interventions continue to advance.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
Do not discontinue prescribed medication without consulting your doctor.
Safety Exclusion Criteria & Red Flags
- Not indicated for: acute febrile illness, recent blood transfusion (within 6 weeks), or if urgent muscle biopsy is required for immediate management.
- Emergency signs: if you experience sudden severe muscle weakness, difficulty breathing, swallowing problems, or chest pain, seek emergency medical care immediately.
- Clinical correlation with a neurologist or clinical geneticist is mandatory; this test alone does not replace a comprehensive neurological evaluation.
Patient FAQ & Clinical Guidance
1. Who should consider this CAPN3 genetic test?
This test is recommended for individuals with progressive proximal muscle weakness, elevated creatine kinase levels, or a family history of limb‑girdle muscular dystrophy. It is also used for carrier screening in consanguineous families or when clinical and electromyography findings suggest LGMD2A.
2. How does this NGS test differ from traditional sequencing?
Unlike Sanger sequencing which targets only a few exons, next‑generation sequencing analyzes the entire CAPN3 coding region including deep intronic boundaries, achieving >99.9% sensitivity for detecting pathogenic variants. This reduces the risk of false‑negative results common with older methods.
3. How do I prepare, and how is home collection arranged?
A simple blood draw or FTA card sample is required; no fasting is needed. Our VIP Mobile Phlebotomy service is available daily from 8 AM to 11 PM with ISO‑certified cold‑chain transport. Contact WhatsApp +971 54 548 8731 to book your appointment and verify insurance coverage.
UAE Regulatory & Data Privacy Adherence
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – full data privacy and genetic data protection.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – secure handling of health information.
- Federal Decree-Law No. 4 of 2016 on Medical Liability – patient consent and clinical safety standards.
- DNA Labs UAE operates under DHA Facility License No. 1143.
Clinical & Logistical Metadata
| Test Name | CAPN3 Gene Limb-Girdle Muscular Dystrophy Type 2A (LGMD2A) Next-Generation Sequencing DNA Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood, Extracted DNA, or One Drop Blood on FTA Card |
| Methodology Used | Next‑Generation Sequencing (NGS) – Full CAPN3 gene coding region analysis |
| ICD-10-CM Code | G71.09, Z13.71, Z31.430 |
| LOINC Code | 81644-7 |
| DHA Facility License & Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians